Founder Series Interview with Steven Hanley
(SAINT LOUIS, MO, July 7, 2016) – Mr. Steven J. Hanley, Chief Executive Officer and co-founder of MediBeacon spoke with Entrepreneur Quarterly (EQ), a publication focused on promoting stories of innovation in St. Louis.
Mr. Hanley sat down with EQ to share how he was drawn to working in the life sciences sector and how this connects with the story of MediBeacon’s creation and growth.
During the interview the origin of MediBeacon as a management buyout from Mallinckrodt, the pharmaceuticals business of Covidien was discussed. Recent developments at the Company including the acquisition of a life science company based in Mannheim, Germany as well as the ongoing clinical studies on the MediBeacon renal function monitoring system were highlighted.
The interview with Mr. Hanley was in the context of the EQ Founder Series.
The full text of the interview is available at EQ_MediBeacon_Interview.
About MediBeacon Inc.
MediBeacon’s mission is to commercialize biocompatible optical diagnostic agents for physiological monitoring, surgical guidance, and imaging of pathological disease in the human population. Several product concepts in these arenas are contained in the MediBeacon Intellectual Property estate. MediBeacon’s portfolio includes a renal function system that uses an optical skin sensor combined with a proprietary fluorescent tracer agent that glows in the presence of light. This system, currently in human trials, provides clinicians continuous real-time monitoring of a patient’s kidney function.
Learn more about MediBeacon at www.medibeacon.com.
# # #
Office – 314-269-5808
Email – email@example.com
1100 Corporate Square Drive
Helix Center, Suite 175
St Louis MO 63132